NASDAQ$HOWL
Werewolf Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · After market close · Investor relations
Briefing
Werewolf Therapeutics Inc reported Q2 2024 financial results with collaboration revenue of $1.1 million and a net loss of $17.2 million.
The company recognized $1.1 million in collaboration revenue during the quarter. Operating expenses totaled $20.1 million, leading to an operating loss of $19.0 million. The net loss was $17.2 million, or $0.40 per basic share.
- Collaboration revenue decreased to $1.1 million from $8.1 million in Q2 2023 due to completion of performance obligations under the Jazz agreement.
- R&D expenses increased to $15.3 million, driven by manufacturing and clinical trial costs for WTX-124 and WTX-330.
- Cash and cash equivalents stood at $135.3 million, supporting operations for at least twelve months.
- The company entered into a new $60 million term loan facility with K2HV, repaying the prior PWB loan.
Headline financials
Revenue & EPS history
Werewolf Therapeutics · Revenue · Quarterly
$1.14M
Forward guidance
Cash and cash equivalents expected to fund operations for at least twelve months from issuance of financial statements.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.1%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+2.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+16.5%
Q2 2022
Best reaction
-7.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2026 | -3.5% | -2.3% | -39.8% | |
| Q3 2025 | -5.0% | -7.4% | -22.0% | |
| Q2 2025 | -1.5% | -5.9% | +5.9% | |
| Q1 2025 | +0.9% | -2.7% | +9.9% | |
| Q4 2024 | -0.9% | -3.4% | -21.5% | |
| Q3 2024 | -5.7% | -11.9% | -26.2% | |
| Q1 2024 | -1.6% | -9.9% | -15.0% | |
| Q4 2023 | -7.4% | -6.1% | -15.8% | |
| Q3 2023 | -0.9% | +3.6% | +28.8% | |
| Q2 2023 | +3.2% | -0.8% | -0.4% | |
| Q1 2023 | -3.3% | -9.9% | +11.2% | |
| Q4 2022 | +6.1% | +9.2% | +3.1% | |
| Q3 2022 | +2.3% | -5.0% | -19.4% | |
| Q2 2022 | +16.5% | +21.3% | +55.2% | |
| Q1 2022 | +3.3% | -12.1% | +1.7% | |
| Q4 2021 | +0.5% | +9.5% | +12.6% | |
| Q3 2021 | +1.8% | +1.6% | -6.7% | |
| Q3 2020 | +1.8% | +1.6% | -6.7% | |
| Q2 2021 | -3.5% | -2.7% | +13.9% | |
| Q2 2020 | -3.5% | -2.7% | +13.9% | |
| Q1 2021 | +1.0% | +5.8% | +22.4% | |
| Q1 2020 | +1.0% | +5.8% | +22.4% | |
| Q4 2020 | +1.0% | +5.8% | +22.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro